Takeda receives fda 510(k) clearance for hyhubtm and hyhubtm duo devices to simplify hyqvia® administration

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that the u.s. food and drug administration (fda) has granted 510(k) clearance for hyhubtm and hyhubtm duo, devices for patients 17 years of age and older that allow hyqvia® [immune globulin infusion (human), 10% with recombinant human hyaluronidase] to be transferred from vials without using a needle in a home environment or clinical setting.2 the hyqvia administration process consists of dual vial unit.
TAK Ratings Summary
TAK Quant Ranking